An intra-aortic balloon pump system is used for the treatment of high-risk cardiac conditions resulting from ischemic heart disease and heart failure. Patients experiencing acute coronary syndromes such as acute myocardial infarction (AMI), cardiogenic shock and unstable angina may require IABP therapy to support and stabilize their cardiac status. The therapy may also be used for high-risk patients who require revascularization procedures, such as percutaneous coronary interventions (PCI) or coronary artery bypass grafting (CABG) procedures, including both on-pump and off-pump CABG procedures. IABP products and therapy may be used before or during CABG or PCI interventions for hemodynamic support.
The IABP market comprises capital equipment pump console units and disposable intra-aortic balloon catheters that serve as the pumping device within the patient's aorta. Datascope, now acquired by Maquet, introduced the first balloon catheter capable of percutaneous insertion. This innovation eliminated the restricted use of IABPs to surgical insertion during CABG procedures and allowed for the expansion of IABPs into the realm of interventional cardiology.
Counterpulsation therapy is used during surgery to provide temporary assistance to the heart. Counterpulsation refers to the inflation and deflation of an intra-aortic balloon synchronized with the heartbeat. The therapy increases the heart's output and the supply of oxygen-rich blood to the heart's coronary arteries while reducing the heart muscle's workload and its oxygen demand. Counterpulsation is performed using intra-aortic balloon pump (IABP) devices.
Key Topics Covered:
U.S. Cardiac Surgery And Heart Valve Device Market Overview